Researchers at the Icahn School of Medicine at Mount Sinai reported that IL‑12‑producing CAR T cells targeting tumor‑associated macrophages (TAMs) improved survival in aggressive mouse models of metastatic ovarian and lung cancer. The engineered T cells killed immunosuppressive macrophages and reprogrammed the tumor microenvironment, enabling endogenous immune responses to control tumor growth. The team showed preclinical efficacy in solid tumor models that are typically refractory to conventional CAR T approaches. The study, published in Cancer Cell, positions myeloid‑directed CAR T as a strategy to overcome the tumor’s protective niche and suggests a path toward broader solid‑tumor applications if safety and manufacturability translate to humans.